| Abstrak/Abstract |
The present study aims to synthesize, evaluation of biological activity, and study docking of new analog compounds A01, B01, C01, and C02 as antibacterial. Claisen-Schmidt method used to synthesize A01, B01, C01, and C02 compounds. The new analog compounds A01, B01, C01, and C02 have antibacterial activity with IC50 values of 37.1 µM, 140 µM, respectively; 79 µM and 117 µM in the aureus; 56.6 µM, 282 µM, 97.6 µM and 186.1 µM in subtilis; 291.2 µM, 1025.9 µM, 679.81 µM and 561.9 µM in E.coli; 29.5 µM, 310.5 µM, 32.9 µM and 130.6 µM in P. aeruginosa; 66.6 µM, 328.6 µM, 49.3 µM and 253.8 µM in mutans; 97.2 µM, 392.2 µM, 129.6 µM, and 191.6 µM in faecialis; 44,811 µM (A113) in C.albicans. Synthesized mono-carbonyl curcumin analog compounds have antibacterial activity through inhibition of bacterial cell wall synthesis. |
